Skip to Content

Megestrol Pregnancy and Breastfeeding Warnings

Megestrol is also known as: Megace, Megace ES

Medically reviewed on October 23, 2017

Megestrol Pregnancy Warnings

Megestrol has been assigned to pregnancy category X by the FDA. An association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and genital abnormalities in male and female fetuses have been reported. Animal studies have revealed a reversible feminizing effect in some male fetuses. There are no controlled data in human pregnancy. Women of childbearing age should be advised to avoid becoming pregnant.

Progestational agents have been reported to have been used beginning with the first trimester of pregnancy in an attempt to prevent habitual abortion.

The risk of hypospadias (normally 0.5% to 0.8% for the general population) may be approximately doubled with exposure to progestational agents.

See references

Megestrol Breastfeeding Warnings

Megestrol is excreted into human milk. Because of the potential for serious adverse reactions due to megestrol in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.

References for breastfeeding information

  1. Nilsson S, Nygren KG, Johansson ED "Megestrol acetate concentrations in plasma and milk during administration of an oral contraceptive containing 4 mg megestrol acetate to nursing women." Contraception 16 (1977): 615-24
  2. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide